Clinical features, predictive correlates, and pathophysiology of immune-related adverse events in immune checkpoint inhibitor treatments in cancer: a short review

References

• PedoeemAAzoulay-AlfaguterIStrazzaMSilvermanGJMorAProgrammed death-1 pathway in cancer and autoimmunityClin Immunol2014153114515224780173
   PubMed Web of Science ®Google Scholar
• DyckLMillsKHGImmune checkpoints and their inhibition in cancer and infectious diseasesEur J Immunol201747576577928393361
   PubMed Web of Science ®Google Scholar
• RaoMValentiniDDodooEZumlaAMaeurerMAnti-PD-1/PD-L1 therapy for infectious diseases: learning from the cancer paradigmInt J Infect Dis20175622122828163164
   PubMed Web of Science ®Google Scholar
• TivolEABorrielloFSchweitzerANLynchWPBluestoneJASharpeAHLoss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4Immunity1995355415477584144
   PubMed Web of Science ®Google Scholar
• WeberJImmune checkpoint proteins: a new therapeutic paradigm for cancer – preclinical background: CTLA-4 and PD-1 blockadeSemin Oncol201037543043921074057
   PubMed Web of Science ®Google Scholar
• KeirMELiangSCGuleriaITissue expression of PD-L1 mediates peripheral T cell toleranceJ Exp Med2006203488389516606670
   PubMed Web of Science ®Google Scholar
• RibasAAdaptive immune resistance: how cancer protects from immune attackCancer Discov20155991591926272491
   PubMed Web of Science ®Google Scholar
• WeintraubKDrug development: releasing the brakesNature20135047480S6S824352363
   PubMed Web of Science ®Google Scholar
• FDADrugs@FDA: FDA approved drug products2014 Available from: http://www.accessdata.fda.gov/scripts/cder/dafAccessed September 14, 2017
   Google Scholar
• FDAFDA approves first cancer treatment for any solid tumor with a specific genetic feature2017 Available from: https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm560167.htmAccessed September 14, 2017
   Google Scholar
• OkazakiTTanakaYNishioRAutoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient miceNat Med20039121477148314595408
   PubMed Web of Science ®Google Scholar
• NishimuraHNoseMHiaiHMinatoNHonjoTDevelopment of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptorImmunity19991114115110485649
   PubMed Web of Science ®Google Scholar
• WolchokJDNeynsBLinetteGIpilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging studyLancet Oncol201011215516420004617
   PubMed Web of Science ®Google Scholar
• TopalianSLHodiFSBrahmerJRSafety, activity, and immune correlates of anti-PD-1 antibody in cancerN Engl J Med2012366262443245422658127
   PubMed Web of Science ®Google Scholar
• WeberJSO’DaySUrbaWPhase I/II study of ipilimumab for patients with metastatic melanomaJ Clin Oncol200826365950595619018089
   PubMed Web of Science ®Google Scholar
• BrahmerJRDrakeCGWollnerIPhase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlatesJ Clin Oncol201028193167317520516446
   PubMed Web of Science ®Google Scholar
• HamidORobertCDaudASafety and tumor responses with lambrolizumab (anti-PD-1) in melanomaN Engl J Med2013369213414423724846
   PubMed Web of Science ®Google Scholar
• PatnaikAKangSPRascoDPhase I study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumorsClin Cancer Res201521194286429325977344
   PubMed Web of Science ®Google Scholar
• RobertCRibasAWolchokJDAnti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trialLancet201438499481109111725034862
   PubMed Web of Science ®Google Scholar
• DayDHansenARImmune-related adverse events associated with immune checkpoint inhibitorsBioDrugs201630657158427848165
   PubMed Web of Science ®Google Scholar
• HaanenJBAGvan ThienenHBlankCUToxicity patterns with immunomodulating antibodies and their combinationsSemin Oncol201542342342825965360
   PubMed Web of Science ®Google Scholar
• WolchokJDKlugerHCallahanMKNivolumab plus ipilimumab in advanced melanomaN Engl J Med2013369212213323724867
   PubMed Web of Science ®Google Scholar
• AntoniaSGoldbergSBBalmanoukianASafety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b studyLancet Oncol201617329930826858122
   PubMed Web of Science ®Google Scholar
• PostowMAChesneyJPavlickACNivolumab and ipilimumab versus ipilimumab in untreated melanomaN Engl J Med2015372212006201725891304
   PubMed Web of Science ®Google Scholar
• LevineJJSomerRAHosoyaHSquillanteCAtezolizumab-induced encephalitis in metastatic bladder cancer: a case report and review of the literatureClin Genitourin Cancer Epub2017316
   Web of Science ®Google Scholar
• HickmottLDe La PeñaHTurnerHAnti-PD-L1 atezolizumab-induced autoimmune diabetes: a case report and review of the literatureTarget Oncol201712223524128255845
   PubMed Web of Science ®Google Scholar
• CarreraWBaartmanBJKosmorskyGA case report of drug-induced myopathy involving extraocular muscles after combination therapy with tremelimumab and durvalumab for non-small cell lung cancerNeuroophthalmology201741314014328512504
   PubMed Web of Science ®Google Scholar
• RosenbergJEHoffman-CensitsJPowlesTAtezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trialLancet2016387100311909192026952546
   PubMed Web of Science ®Google Scholar
• MassardCGordonMSSharmaSSafety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancerJ Clin Oncol201634263119312527269937
   PubMed Web of Science ®Google Scholar
• KaufmanHLRussellJHamidOAvelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trialLancet Oncol201617101374138527592805
   PubMed Web of Science ®Google Scholar
• GulleyJLRajanASpigelDRAvelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN solid tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trialLancet Oncol201718559961028373005
   PubMed Web of Science ®Google Scholar
• HeeryCRO’Sullivan-CoyneGMadanRAAvelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN solid tumor): a phase 1a, multicohort, dose-escalation trialLancet Oncol201718558759828373007
   PubMed Web of Science ®Google Scholar
• ApoloABInfanteJRBalmanoukianAAvelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, phase Ib studyJ Clin Oncol201735192117212428375787
   PubMed Web of Science ®Google Scholar
• McDermottDFSosmanJASznolMAtezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase Ia studyJ Clin Oncol201634883384226755520
   PubMed Web of Science ®Google Scholar
• HerbstRSSoriaJ-CKowanetzMPredictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patientsNature2014515752856356725428504
   PubMed Web of Science ®Google Scholar
• Abdel-WahabNShahMSuarez-AlmazorMEAdverse events associated with immune checkpoint blockade in patients with cancer: a systematic review of case reportsPLoS One2016117e016022127472273
   PubMed Web of Science ®Google Scholar
• AyaFRuiz-EsquideVViladotMVasculitic neuropathy induced by pembrolizumabAnn Oncol201728243343427864214
   PubMed Web of Science ®Google Scholar
• de VelascoGBermasBChoueiriTKAutoimmune arthropathy and uveitis as complications of programmed death 1 inhibitor treatmentArthritis Rheumatol201668255655726314277
   PubMed Web of Science ®Google Scholar
• GelsominoFVitaleGD’ErricoABertuzziCAndreonePArdizzoniANivolumab-induced cholangitic liver disease: a novel form of serious liver injuryAnn Oncol201728367167227993797
   PubMed Web of Science ®Google Scholar
• JungKZengXBilusicMNivolumab-associated acute glomerulonephritis: a case report and literature reviewBMC Nephrol201617118827876011
   PubMed Web of Science ®Google Scholar
• KhokharMOKettleJPallaARDebilitating skin toxicity associated with pembrolizumab therapy in an 81-year-old female with malignant melanomaCase Rep Oncol20169383383928101032
   PubMedGoogle Scholar
• LarsabalMMartiAJacqueminCVitiligo-like lesions occurring in patients receiving anti-programmed cell death-1 therapies are clinically and biologically distinct from vitiligoJ Am Acad Dermatol201776586387028094061
   PubMed Web of Science ®Google Scholar
• LäubliHBalmelliCBossardMPfisterOGlatzKZippeliusAAcute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanomaJ Immunother Cancer2015311125901283
   PubMed Web of Science ®Google Scholar
• OhtsukaMMiuraTMoriTIshikawaMYamamotoTOccurrence of psoriasiform eruption during nivolumab therapy for primary oral mucosal melanomaJAMA Dermatol2015151779725875052
   PubMed Web of Science ®Google Scholar
• SemperHMuehlbergFSchulz-MengerJAlleweltMGrohéCDrug-induced myocarditis after nivolumab treatment in a patient with PDL1-negative squamous cell carcinoma of the lungLung Cancer20169911711927565924
   PubMed Web of Science ®Google Scholar
• SimonelliMDi TommasoLBarettiMSantoroAPathological characterization of nivolumab-related liver injury in a patient with glioblastomaImmunotherapy20168121363136928000537
   PubMed Web of Science ®Google Scholar
• TanakaRMaruyamaHTomidokoroYNivolumab-induced chronic inflammatory demyelinating polyradiculoneuropathy mimicking rapid-onset Guillain–Barre syndrome: a case reportJpn J Clin Oncol201646987587827380808
   PubMed Web of Science ®Google Scholar
• TardyMPGastaudLBoscagliAPeyradeFGallaminiAThyssAAutoimmune hemolytic anemia after nivolumab treatment in Hodgkin lymphoma responsive to immunosuppressive treatment. A case reportHematol Oncol Epub2016819
   Web of Science ®Google Scholar
• CappelliLCGutierrezAKBaerANInflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumabAnn Rheum Dis2017761435027307501
   PubMed Web of Science ®Google Scholar
• HofmannLForschnerALoquaiCCutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapyEur J Cancer20166019020927085692
   PubMed Web of Science ®Google Scholar
• HorvatTZAdelNGDangTOImmune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer CenterJ Clin Oncol201533283193319826282644
   PubMed Web of Science ®Google Scholar
• AleksovaJLauPKHSoldatosGMcArthurGGlucocorticoids did not reverse type 1 diabetes mellitus secondary to pembrolizumab in a patient with metastatic melanomaBMJ Case Rep Epub20161123
   Google Scholar
• MiyoshiYOgawaOOyamaYNivolumab, an anti-programmed cell death-1 antibody, induces fulminant type 1 diabetesTohoku J Exp Med2016239215515827297738
   PubMed Web of Science ®Google Scholar
• Martin-LiberalJFurnessAJJoshiKPeggsKSQuezadaSALarkinJAnti-programmed cell death-1 therapy and insulin-dependent diabetes: a case reportCancer Immunol Immunother201564676576725828465
   PubMed Web of Science ®Google Scholar
• HughesJVudattuNSznolMPrecipitation of autoimmune diabetes with anti-PD-1 immunotherapyDiabetes Care2015384e55e5725805871
   PubMed Web of Science ®Google Scholar
• TrainerHHulsePHighamCETrainerPLoriganPHyponatraemia secondary to nivolumab-induced primary adrenal failureEndocrinol Diabetes Metab Case Rep Epub2016111
   Google Scholar
• RyderMCallahanMPostowMAWolchokJFaginJAEndocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institutionEndocr Relat Cancer201421237138124610577
   PubMed Web of Science ®Google Scholar
• OngMIbrahimAMBourassa-BlanchetteSCanilCFairheadTKnollGAntitumor activity of nivolumab on hemodialysis after renal allograft rejectionJ Immunother Cancer2016416427777773
   PubMed Web of Science ®Google Scholar
• SpainLHigginsRGopalakrishnanKTurajlicSGoreMLarkinJAcute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanomaAnn Oncol20162761135113726951628
   PubMed Web of Science ®Google Scholar
• LipsonEJBagnascoSMMooreJTumor regression and allograft rejection after administration of anti-PD-1N Engl J Med20163749896898
   PubMed Web of Science ®Google Scholar
• BarnettRBartaVSJhaveriKDPreserved renal-allograft function and the PD-1 pathway inhibitor nivolumabN Engl J Med2017376219119228076715
   PubMed Web of Science ®Google Scholar
• AlhamadTVenkatachalamKLinetteGPBrennanDCCheckpoint inhibitors in kidney transplant recipients and the potential risk of rejectionAm J Transplant20161641332133326752406
   PubMed Web of Science ®Google Scholar
• OwonikokoTKKumarMYangSCardiac allograft rejection as a complication of PD-1 checkpoint blockade for cancer immunotherapy: a case reportCancer Immunol Immunother2017661455027771741
   PubMed Web of Science ®Google Scholar
• WanchooRRiellaLVUppalNNImmune checkpoint inhibitors in the cancer patient with an organ transplantJ Onco-Nephrol2017114248
   Google Scholar
• BehlingJKaesJMünzelTGrabbeSLoquaiCNew-onset third-degree atrioventricular block because of autoimmune-induced myositis under treatment with anti-programmed cell death-1 (nivolumab) for metastatic melanomaMelanoma Res201727215515827977496
   PubMed Web of Science ®Google Scholar
• GibsonRDelauneJSzadyAMarkhamMSuspected autoimmune myocarditis and cardiac conduction abnormalities with nivolumab therapy for non-small cell lung cancerBMJ Case Rep Epub2016720
   Google Scholar
• PallaARKennedyDMosharrafHDollDAutoimmune hemolytic anemia as a complication of nivolumab therapyCase Rep Oncol20169369169727920704
   PubMed Web of Science ®Google Scholar
• NishinoMShollLMHatabuHRamaiyaNHHodiFSAnti-PD-1-related pneumonitis during cancer immunotherapyN Engl J Med2015373328829026176400
   PubMed Web of Science ®Google Scholar
• MauriceCSchneiderRKiehlTSubacute CNS demyelination after treatment with nivolumab for melanomaCancer Immunol Res20153121299130226419960
   PubMed Web of Science ®Google Scholar
• ShiraiTSanoTKamijoFAcetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanomaJpn J Clin Oncol2016461868826491202
   PubMed Web of Science ®Google Scholar
• LoochtanAINickolichMSHobson-WebbLDMyasthenia gravis associated with ipilimumab and nivolumab in the treatment of small cell lung cancerMuscle Nerve201552230730825759003
   PubMed Web of Science ®Google Scholar
• PhadkeSDGhabourRSwickBLSwensonAMilhemMZakhariaYPembrolizumab therapy triggering an exacerbation of preexisting autoimmune diseaseJ Investig Med High Impact Case Rep2016442324709616674316
   Google Scholar
• KimuraTFukushimaSMiyashitaAMyasthenic crisis and polymyositis induced by one dose of nivolumabCancer Sci201610771055105827420474
   PubMed Web of Science ®Google Scholar
• GonzalezNLPuwanantALuAMarksSMŽivkoviSAMyasthenia triggered by immune checkpoint inhibitors: new case and literature reviewNeuromuscul Disord201727326626828109638
   PubMed Web of Science ®Google Scholar
• KongBYMicklethwaiteKPSwaminathanSKeffordRFCarlinoMSAutoimmune hemolytic anemia induced by anti-PD-1 therapy in metastatic melanomaMelanoma Res201626220220426795275
   PubMed Web of Science ®Google Scholar
• KatoYOtsukaAMiyachiYKabashimaKExacerbation of psoriasis vulgaris during nivolumab for oral mucosal melanomaJ Eur Acad Dermatol Venereol20163010e89e9126388113
   PubMed Web of Science ®Google Scholar
• NaritaTOisoNTaketomoYSerological aggravation of autoimmune thyroid disease in two cases receiving nivolumabJ Dermatol201643221021426198822
   PubMed Web of Science ®Google Scholar
• CotliarJQuerfeldCBoswellWJRajaNRazDChenRPembrolizumab-associated sarcoidosisJAAD Case Rep20162429029327504482
   PubMedGoogle Scholar
• LauKHVKumarAYangIHNowakRJExacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumabMuscle Nerve201654115716127065302
   PubMed Web of Science ®Google Scholar
• BeckKMDongJGeskinLJDisease stabilization with pembrolizumab for metastatic acral melanoma in the setting of autoimmune bullous pemphigoidJ Immunother Cancer2016412027096097
   PubMed Web of Science ®Google Scholar
• BeckKEBlansfieldJATranKQEnterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4J Clin Oncol200624152283228916710025
   PubMed Web of Science ®Google Scholar
• JohnsonDBSullivanRJOttPAIpilimumab therapy in patients with advanced melanoma and preexisting autoimmune disordersJAMA Oncol20162223426633184
   PubMed Web of Science ®Google Scholar
• MenziesAMJohnsonDBRamanujamSAnti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumabAnn Oncol2016282368376
   Web of Science ®Google Scholar
• PedersenMAndersenRNørgaardPSuccessful treatment with ipilimumab and interleukin-2 in two patients with metastatic melanoma and systemic autoimmune diseaseCancer Immunol Immunother201463121341134625227926
   PubMed Web of Science ®Google Scholar
• UemuraMTrinhVAHaymakerCSelective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn’s disease: a case reportJ Hematol Oncol2016918127595932
   PubMed Web of Science ®Google Scholar
• Freeman-KellerMKimYCroninHRichardsAGibneyGWeberJSNivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomesClin Cancer Res201622488689426446948
   PubMed Web of Science ®Google Scholar
• SanlorenzoMVujicIDaudAPembrolizumab cutaneous adverse events and their association with disease progressionJAMA Dermatol201515111120626222619
   PubMed Web of Science ®Google Scholar
• HuaCBoussemartLMateusCAssociation of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumabJAMA Dermatol201615214526501224
   PubMed Web of Science ®Google Scholar
• HuangSKSOkamotoTMortonDLHoonDSBAntibody responses to melanoma/melanocyte autoantigens in melanoma patientsJ Invest Dermatol199811146626679764850
   PubMed Web of Science ®Google Scholar
• NordlundJKirkwoodJForgetBMiltonGVitiligo in patients with metastatic melanoma: a good prognostic signJ Am Acad Dermatol1983956896966643767
   PubMed Web of Science ®Google Scholar
• BystrynJCRigelDFriedmanRJKopfAPrognostic significance of hypopigmentation in malignant melanomaArch Dermatol19871238105310553631983
   PubMedGoogle Scholar
• JohnsonDBBalkoJMComptonMLFulminant myocarditis with combination immune checkpoint blockadeN Engl J Med2016375181749175527806233
   PubMed Web of Science ®Google Scholar
• ChengFLoscalzoJAutoimmune cardiotoxicity of cancer immunotherapyTrends Immunol2017382777827919707
   PubMed Web of Science ®Google Scholar
• SpainLLarkinJMartin-LiberalJDetermining predictive factors for immune checkpoint inhibitor toxicity: response to Letter to the Editors “A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome”Cancer Immunol Immunother201665676977027194054
   PubMed Web of Science ®Google Scholar
• FujisawaYYoshinoKOtsukaAFluctuations in routine blood count might signal severe immune-related adverse events in melanoma patients treated with nivolumabJ Dermatol Sci Epub2017716
   Web of Science ®Google Scholar